Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Patent Reform Act of 2007
I agee. I 'm not sure why everyone is dismissing this so easily. Less than 2 weeks ago the very company we are invested in told us the pending legislation would have serious ramifications. They did not address any pending revisions to the bill thus leading us to believe in it's current format it would have a negative impact on potential earnings. Yesterday someone mentioned perhaps the concern was dealing more with TPL's future revenue in other products. I don't believe that to be the case otherwise, a publicly traded company would not release a shareholder letter containing information eluding to potential negative impact on future revenue. This reminds me of the Markman ruling, Mr. Leckrone comes out and states one of the claims would need further scrutiny. People start assuming it's a threat to ARM when in fact it should have been taken at face value. One of the claims did not go in our favor plain and simple. I think the pending legislation is no different, both companies are being straight forward with us. Look folks if this passes it won't be good. If that's not the case than it is Mr. Turley's job to inform investors otherwise.
Share
New Message
Please login to post a reply